TGFB2 and central nervous system cancer: In a preclinical study using 9L glioma in Fischer 944 rats, intracranial TGFB-2 ASO administration and vaccination with exposed glioma cells together not only inhibited TGFB protein production in vivo as expected but also significantly increased the survival times in comparison with either the vaccine alone or no therapy [58].